drugset / Trial / NCT07229599
A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first-in-human, open-label, multicenter Phase I/II study of MHB036C combined with MHB039A or other anti-tumor therapy in patients with advanced lung cancer. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB036C combined with MHB039A or other anti-tumor therapies.
Timeline
- Start
- 2025-05-09
- Primary completion
- 2029-05
- Completion
- 2030-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Firmonertinib | Small molecule | — | Oral |
| Subject | MHB036C for Injection | Unknown | — | Intravenous |
| Subject | MHB039A for Injection | Unknown | — | Intravenous |